Cargando…

CD16(+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice

Patients with acute myeloid leukemia (AML) often relapse after initial therapy because of persistence of leukemic stem cells that frequently express the IL-3 receptor alpha chain CD123. Natural killer (NK) cell-based therapeutic strategies for AML show promise and we explore the NK cell lines, NK-92...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Brent A., Wang, Xing-Hua, Leyton, Jeffrey V., Maghera, Sonam, Deif, Bishoy, Reilly, Raymond M., Minden, Mark D., Keating, Armand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165813/ https://www.ncbi.nlm.nih.gov/pubmed/29976748 http://dx.doi.org/10.3324/haematol.2017.187385

Ejemplares similares

A radiolabeled antibody targeting CD123(+) leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML
por: Leyton, Jeffrey V., et al.
Publicado: (2015)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1
por: Ernst, Daniel, et al.
Publicado: (2019)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
por: Gauthier, Laurent, et al.
Publicado: (2023)

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission
por: Xie, L H, et al.
Publicado: (2017)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
por: Althaus, Jonas, et al.
Publicado: (2023)

Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy
por: Navarrete-Galvan, Lydia, et al.
Publicado: (2022)

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
por: Caruso, Simona, et al.
Publicado: (2022)

A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
por: Williams, Brent A., et al.
Publicado: (2017)

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
por: Boissel, Laurent, et al.
Publicado: (2013)

Diagnostic Challenges of CD4(+)/CD56(+)/CD123(+) hematological neoplasms
por: Thiago, Leandro S., et al.
Publicado: (2013)

Predicting CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy
por: Makkouk, Amani, et al.
Publicado: (2015)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

Development Of [(211)At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies
por: Laszlo, George S., et al.
Publicado: (2022)

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
por: Ehninger, A, et al.
Publicado: (2014)

92R Monoclonal Antibody Inhibits Human CCR9(+) Leukemia Cells Growth in NSG Mice Xenografts
por: Somovilla-Crespo, Beatriz, et al.
Publicado: (2018)

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
por: Roex, Gils, et al.
Publicado: (2022)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
por: Cai, Tianyu, et al.
Publicado: (2022)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Analysis of NK-92 cytotoxicity in nasopharyngeal carcinoma cell lines and patient-derived xenografts using impedance-based growth method
por: Abd Talib, Fatin Nur Asyiqin, et al.
Publicado: (2023)

In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells
por: Tomalka, Amanda G., et al.
Publicado: (2018)

Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells
por: Panwong, Suthida, et al.
Publicado: (2021)

In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment
por: Grote, Stefan, et al.
Publicado: (2021)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

Detection of Antibody-Dependent Cell-Mediated Cytotoxicity—Supporting Antibodies by NK-92-CD16A Cell Externalization of CD107a: Recognition of Antibody Afucosylation and Assay Optimization
por: Cruz Amaya, Judith, et al.
Publicado: (2023)

Prognostic value of CD25/CD123 pattern of expression in acute myeloid leukemia patients with normal cytogenetic
por: Aref, Salah, et al.
Publicado: (2020)

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
por: Mani, Rajeswaran, et al.
Publicado: (2018)

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia
por: Angelova, Evgeniya, et al.
Publicado: (2019)

Prolonged localisation of a monoclonal antibody against CEA in a human colon tumour xenograft.
por: Harwood, P. J., et al.
Publicado: (1985)

Novel Mouse Xenograft Models Reveal a Critical Role of CD4(+) T Cells in the Proliferation of EBV-Infected T and NK Cells
por: Imadome, Ken-Ichi, et al.
Publicado: (2011)

Altered Expression of Substance P and NK1R in CCR3(+) and CD123(+)HLA-DR(−) Basophils Under Airway Allergic Conditions
por: Geng, Shiyang, et al.
Publicado: (2022)

Reduction of the CD16(−)CD56(bright) NK Cell Subset Precedes NK Cell Dysfunction in Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Increased Activity of a NK-Specific CAR-NK Framework Targeting CD3 and CD5 for T-Cell Leukemias
por: Voynova, Elisaveta, et al.
Publicado: (2022)

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
por: Testa, Ugo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jeq6eqqio72l1l6hn9dg820rg6